BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $189 from $178 and keeps an Outperform rating on the shares. The firm ...

Quest Diagnostics (NYSE:DGX) recently introduced the AD-Detect™ blood test, a significant development aimed at confirming Alzheimer's-related amyloid brain pathology. Over the last quarter, the ...

Bank of America upped their price target on shares of Quest Diagnostics from $179.00 to $182.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. UBS Group lifted ...

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Fintel reports that on April 2, 2025, Redburn Atlantic initiated coverage of Quest Diagnostics (NYSE:DGX) with a Buy recommendation. Analyst Price Forecast Suggests 7.56% Upside As of March 19, 2025, ...

During the last three months, 9 analysts shared their evaluations of Quest Diagnostics DGX, revealing diverse outlooks from bullish to bearish. In the table below, you'll find a summary of their ...

Detailed price information for Align Technology (ALGN-Q) from The Globe and Mail including charting and trades.

Canadian-first strategy. One of them is in the health sector, where U.S. giants supplying expensive medical equipment often ...